Oxipurinol

Chemical properties

Off White Solid

The Uses of Oxipurinol

A metabolite of Allopurinol.

The Uses of Oxipurinol

4,6-Dihydroxy-1H-pyrazolo[3,4-d]pyrimidine is an inhibitor to study the specificity and kinetics of xanthine oxidase. It is also used as an anti-inflammatory agent via inhibition of xanthine oxidase.

The Uses of Oxipurinol

Oxypurinol, an allopurinol metabolite, is used as an inhibitor to study the specificity and kinetics of of xanthine oxidase(s). Oxypurinol is also used as an anti-inflammatory agent via inhibition of xanthine oxidase.

What are the applications of Application

Oxipurinol is a metabolite of allopurinol used as an inhibitor to study the specificity and kinetics of of xanthine oxidase(s)

Definition

ChEBI: A pyrazolopyrimidine that is 4,5,6,7-tetrahydro-H-pyrazolo[3,4-d]pyrimidine substituted by oxo groups at positions 4 and 6.

Biological Activity

oxipurinol is a xanthine oxidoreductase inhibitor.xanthine oxidoreductase (xo), a complex molybdoflavoenzyme present in milk and many other tissues, has been studied for many years. xo is generally recognized as a critical enzyme in purine catabolism.

Biochem/physiol Actions

An allopurinol metabolite.

in vitro

allopurinol could be rapidly oxidized by xo to its active metabolite oxypurinol (both isosteres of hypoxanthine and xanthine, respectively), which also could inhibit xo. oxypurinol was identified as a noncompetitive inhibitor of xo; the formation of this compound was reported to be responsible for much of the pharmacological activity of allopurinol. moreover, both allopurinol and oxypurinol showed free radical scavenging effects in isolated hearts, and exerted cardioprotective effects despite no detectable xo activities [1].

in vivo

animal study found that in the vasculature of hypercholesterolemic rabbits, oxypurinol treatment led to a decrease in vascular free radical production [1].

References

[1] p. pacher, a. nivorozhkin and c. szabó. therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. pharmacological reviews 58(1), 87-114 (2006).
[2] day ro, graham gg, hicks m, mclachlan aj, stocker sl, williams km. clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. clin pharmacokinet. 2007;46(8):623-44.